This retrospective study of a large database investigated the effect of DM pharmacologic agents on AD incidence to assess whether metformin has a more significant protective benefit against neurodegenerative processes than GLP-1, sulfonylureas, and short-acting insulin [18,21]. Here, GLP1R is linked to diabetes mellitus.